Related Experiment Video
Updated: Jul 17, 2026

07:13
Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
Published on: May 24, 2024
Newer vascular targets: endosialin (review)
1Genzyme Corporation, Framingham, MA 01701-9322, USA. beverly.teicher@genzyme.com
International Journal of Oncology
|January 5, 2007
Summary
Identifying specific markers on tumor blood vessels is difficult. Researchers found endosialin, a cell surface protein, is selectively expressed on tumor vasculature and stroma, offering potential for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Identifying unique cell surface markers on tumor vasculature is a significant challenge in cancer research.
- Endothelial cells form the inner lining of blood vessels and play a crucial role in tumor growth and metastasis.
Purpose of the Study:
- To identify novel cell surface markers selectively expressed by tumor vasculature.
- To evaluate the potential of identified markers for targeted cancer therapy.
Main Methods:
- Isolation of endothelial cells from fresh human tumor specimens.
- RNA-based gene expression analysis to compare gene profiles of tumor vasculature versus normal vasculature.
- Confirmation of selective marker expression through further analysis.
Main Results:
- Gene expression analysis revealed limited protein differences between tumor and normal vasculature, highlighting the specialized nature of endothelial cells.
- Endosialin was identified as a cell surface marker selectively expressed by tumor vasculature and associated stroma.
- The expression pattern of endosialin suggests its potential utility in cancer treatment strategies.
Conclusions:
- Endothelial cells exhibit specialized characteristics, with few proteins uniquely distinguishing tumor vasculature.
- Endosialin is a promising cell surface marker for targeting tumor vasculature and stroma.
- The selective expression of endosialin presents a potential avenue for developing novel cancer therapies.
